Skip to Main Content

Paper Details

Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin.
Oncotarget
10
2019
Author NameAffiliation
John M MariadasonOlivia Newton-John Cancer Research Institute, La Trobe University School of Cancer Medicine
  • 1 - 1

Datasets

Release 1.2